Usefulness of GDF-15 as a biomarker of respiratory worsening in COVID-19 patients.
A. Mariscal (Barcelona, Spain), L. Alserawan (Barcelona, Spain), I. Castellví (Barcelona, Spain), E. Ortiz (Barcelona, Spain), P. Peñacoba (Barcelona, Spain), T. Franco-Leyva (Barcelona, Spain), J. Tandaipán (Barcelona, Spain), L. Martínez-Martínez (Barcelona, Spain), H. Corominas (Barcelona, Spain), P. Domingo (Barcelona, Spain), C. Juárez (Barcelona, Spain), D. Castillo (Barcelona, Spain)
Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Mariscal (Barcelona, Spain), L. Alserawan (Barcelona, Spain), I. Castellví (Barcelona, Spain), E. Ortiz (Barcelona, Spain), P. Peñacoba (Barcelona, Spain), T. Franco-Leyva (Barcelona, Spain), J. Tandaipán (Barcelona, Spain), L. Martínez-Martínez (Barcelona, Spain), H. Corominas (Barcelona, Spain), P. Domingo (Barcelona, Spain), C. Juárez (Barcelona, Spain), D. Castillo (Barcelona, Spain). Usefulness of GDF-15 as a biomarker of respiratory worsening in COVID-19 patients.. 673
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: